Hims & Hers earnings up next: Can GLP-1 boom drive profit?

Ahead of Monday’s Q3 report, analysts expect Hims & Hers to earn $0.06 per share on $892.88 million in revenue, up 49% year over year, versus a $0.37-per-share loss in Q2. Truist’s proprietary data showed GLP-1 billings down 16% month over month in September, although Q3 billings were up 22% sequentially; the analyst said September membership figures are provisional. Investors will also assess profitability and the company’s Eli Lilly partnership to offer branded weight-loss drugs, while a securities class action related to privacy practices remains a legal overhang.

Analysis

The key underwriting question is whether HIMS is acquiring durable customers or renting short-duration GLP-1 demand. September’s deterioration in third-party transaction indicators is a warning on retention and revenue quality, but it is not conclusive: provisional data and branded-drug availability could change the mix. The earnings release may not disclose the cohort retention or product-level contribution economics needed to settle that question.

The Lilly arrangement potentially lowers HIMS’s exposure to compounding-related regulatory disruption and gives LLY another customer-acquisition channel. The trade-off may be lower HIMS economics per prescription and less differentiation; Lilly could also capture the customer relationship directly over time. Do not capitalize the partnership as a margin-positive catalyst until pricing, fulfillment responsibilities, and repeat-purchase behavior are clearer. Other telehealth and weight-loss providers face the same substitution pressure if customers migrate toward branded products.

Near term, the print is a binary catalyst: an EPS beat alone is weak evidence if GLP-1 retention or gross margin deteriorates. Over 1–3 months, watch reported subscriber trends, product mix, and management’s explanation of September softness. Over 6–18 months, regulatory treatment of compounded GLP-1s and branded-drug access determine whether HIMS is a scalable distribution platform or a lower-margin intermediary. The thesis is falsified positively by stabilizing retention with maintained gross margin; negatively by continued GLP-1 attrition or margin compression despite revenue growth.

Key Decisions for Investors

• Avoid a large directional HIMS position into the earnings event; the available evidence does not resolve whether demand softness is temporary or structural, and the company-specific unit economics remain unverified.
• Post-print, consider a staged HIMS long only if management demonstrates stable gross margin alongside improving GLP-1 retention or repeat purchasing. Risk/reward is attractive only if growth is translating into durable contribution economics, not merely higher top-line sales.
• If GLP-1 weakness persists and gross margin declines, consider a defined-risk bearish HIMS options position after the event, when implied volatility has repriced; invalidate it on evidence of retention stabilization and margin resilience.
• Treat LLY as a watch rather than a partnership-driven trade: verify whether HIMS is delivering incremental branded-drug volume and whether the channel economics are material. Failure to disclose these details is not evidence of meaningful earnings contribution.